US regulators fast-track novel leukemia therapy

July 7, 2014

US regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear.

The personalized immunotherapy known as CTL019 was developed by the University of Pennsylvania and was designated a "breakthrough therapy" by the US Food and Drug Administration.

That means the will benefit from a speedier than average review process and will get extra attention from the FDA toward development for market.

It is the first to receive the breakthrough designation, and only the fifth biologic agent so far.

The approach works by extracting a patient's T-cells, then genetically programming them in the lab to target that produce a protein called CD19.

The altered T-cells are then re-injected into the patient's body, where they multiply and attack cancer.

Researchers reported last year that of 27 patients, including 22 children and five adults, with acute lymphoblastic leukemia, 89 percent had a complete response to the therapy, meaning their became undetectable.

The first child to receive the treatment, Emily Whitehead, in May marked two years of being in remission, and the first adult patient has been in remission for one year.

"Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June.

The university in 2012 teamed up with pharmaceutical company Novartis to develop and license personalized chimeric antigen receptor (CAR) T cell therapies for the treatment of cancers.

In addition to the ongoing trials for , trials using CTL019 began in the summer of 2010 in patients with relapsed and refractory .

It is also being tried in patients with non-Hodgkin lymphoma and myeloma.

More research is also under way into CAR therapies for mesothelioma, ovarian, breast and pancreatic cancers.

Explore further: T cell immunotherapy: Promising results in children and adults with leukemia

Related Stories

T cell immunotherapy: Promising results in children and adults with leukemia

December 7, 2013
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune ...

Engineered immune cells produce complete response in child with an aggressive pediatric leukemia

December 9, 2012
By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed ...

Immunotherapy showed promising antileukemia activity in pediatric patients

April 7, 2013
Researchers using patients' own immune cells in an immunotherapy approach called "anti-CD19 chimeric antigen receptor (CAR) T-cell therapy," achieved responses in children whose acute lymphocytic leukemia (ALL) had returned ...

T-cell therapy eradicates an aggressive leukemia in two children

March 25, 2013
Two children with an aggressive form of childhood leukemia had a complete remission of their disease-showing no evidence of cancer cells in their bodies-after treatment with a novel cell therapy that reprogrammed their immune ...

Immunotherapy is new revolution in cancer fight

June 2, 2014
Immunotherapy has made great strides against cancers like melanoma that were once believed incurable, though scientists still do not understand why it works well in some cases but not others.

Cell therapy shows remarkable ability to eradicate cancer in clinical study

February 19, 2014
Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Psilly_T
1 / 5 (1) Jul 10, 2014
Awesome news!
But will insurance cover something like this or would we end up in the same situation as hepatitis C? =x
Still awesome

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.